



Hans-Georg Rammensee

Kontakt

Hans-Georg Rammensee

Publikationen (16)

Hoenisch Gravel N, Nelde A, Bauer J, Mühlenbruch L, Schroeder S, Neidert M, Scheid J, Lemke S, Dubbelaar M, Wacker M, Dengler A, Klein R, Mauz P, Löwenheim H, Hauri-Hohl M, Martin R, Hennenlotter J, Stenzl A, Heitmann J, Salih H, Rammensee H, Walz J. TOF mass spectrometry-based immunopeptidomics refines tumor antigen identification. *Nat Commun* 2023; 14:7472.

Medici G, Freudenmann L, Velz J, Wang S, Kapolou K, Paramasivam N, Mühlenbruch L, Kowalewski D, Vasella F, Bilich T, Frey B, Dubbelaar M, Patterson A, Zeitlberger A, Silginer M, Roth P, Weiss T, Wirsching H, Krayenbühl N, Bozinov O, Regli L, Rammensee H, Rushing E, Sahm F, Walz J, Weller M, Neidert M. A T-cell antigen atlas for meningioma: novel options for immunotherapy. *Acta Neuropathol* 2023; 146:173-190.

Naghavian R, Faigle W, Oldrati P, Wang J, Toussaint N, Qiu Y, Medici G, Wacker M, Freudenmann L, Bonté P, Weller M, Regli L, Amigorena S, Rammensee H, Walz J, Brugger S, Mohme M, Zhao Y, Sospedra M, Neidert M, Martin R. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. *Nature* 2023; 617:807-817.

Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. *Sci Immunol* 2022; 7:eabn9644.

Kubiniok P, Marcu A, Bichmann L, Kuchenbecker L, Schuster H, Hamelin D, Duquette J, Kovalchik K, Wessling L, Kohlbacher O, Rammensee H, Neidert M, Sirois I, Caron E. Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues. *iScience* 2022; 25:103768.

Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. *Oncoimmunology* 2021; 10:2006893.

Nelde A, Rammensee H, Aulitzky W, Illerhaus G, Denzlinger C, Neidert M, Bauer J, Marcu A, Heitmann J, Roerden M, Salih H, Bilich T, Maringer Y, Walz J. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. *Front Immunol* 2021; 12:705974.

Bilich T, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee H, Salih H, Berner F, Wacker M, Roerden M, Maringer Y, Nelde A, Heitmann J, Dubbelaar M, Peter A, Hörber S, Bauer J, Rieth J, Walz J. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. *Cancer Discov* 2021; 11:1982-1995.

Marcu A, Walz J, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler M, Erhard F, Schlosser A, Kohlbacher O, Stevanovic S, Rammensee H, Kapolou K, Martin R, Hauri-Hohl M, Bichmann L, Kuchenbecker L, Kowalewski D, Freudenmann L, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Neidert M. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. *J Immunother Cancer* 2021; 9

Bilich T, Stevanovic S, Rammensee H, Neidert M, Schuhmacher J, Lübke M, Marcu A, Besemer B, Weisel K, Salih H, Roerden M, Walz S, Bauer J, Nelde A, Walz J. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. *Blood Cancer J* 2020; 10:24.

Bilich T, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper J, Klein R, Kohlbacher O, Kanz L, Rammensee H, Stevanovic S, Brümmendorf T, Schemionek M, Rieth J, Nelde A, Bichmann L, Roerden M, Salih H, Kowalewski D, Schuster H, Tsou C, Marcu A, Neidert M, Lübke M, Walz J. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. *Blood* 2018; 133:550-565.

Neidert M, Rammensee H, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Wolpert F, Walz J, Kowalewski D, Silginer M, Kapolou K, Backert L, Freudenmann L, Peper J, Marcu A, Wang S, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. *Acta Neuropathol* 2018; 135:923-938.

Backert L, Stevanovic S, Rammensee H, Weisel K, Kohlbacher O, Salih H, Kanz L, Niederwieser D, Vucinic V, Brümmendorf T, Schemionek M, Neidert M, Berlin C, Schuster H, Walz S, Kowalewski D, Walz J. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. *Oncotarget* 2017; 8:43915-43924.

Skabytska Y, Götz F, Röcken M, Schaller M, Rammensee H, Volz T, Kempf W, Demircioglu D, Guenova E, Chen K, Kaesler S, Köberle M, Günther C, Wölbing F, Biedermann T. Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. *Immunity* 2014; 41:762-75.

Neidert M, Dietrich P, Herold-Mende C, Rammensee H, Honegger J, Melms A, Christ L, Trautwein N, Trautwein C, Schoor O, Stevanovic S. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. *J Neurooncol* 2012; 111:285-94.

Dengjel J, Rammensee H, Driessen C, Brock R, Kalbacher H, Brandenburg J, Altenberend F, Kreymborg K, Müller M, Kraus M, Reich M, Fischer R, Schoor O, Stevanovic S. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102:7922-7.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch